These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 30471682)

  • 21. Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications.
    Kraehenmann R
    Curr Neuropharmacol; 2017; 15(7):1032-1042. PubMed ID: 28625125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychedelics and Neural Plasticity: Therapeutic Implications.
    Grieco SF; Castrén E; Knudsen GM; Kwan AC; Olson DE; Zuo Y; Holmes TC; Xu X
    J Neurosci; 2022 Nov; 42(45):8439-8449. PubMed ID: 36351821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Therapeutic Potential of Psilocybin.
    Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L
    Molecules; 2021 May; 26(10):. PubMed ID: 34063505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psychedelics in the treatment of unipolar mood disorders: a systematic review.
    Rucker JJ; Jelen LA; Flynn S; Frowde KD; Young AH
    J Psychopharmacol; 2016 Dec; 30(12):1220-1229. PubMed ID: 27856684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Past and Future of Psychedelic Science: An Introduction to This Issue.
    Doblin RE; Christiansen M; Jerome L; Burge B
    J Psychoactive Drugs; 2019; 51(2):93-97. PubMed ID: 31132970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Studies with psychedelic drugs in human volunteers.
    Sellers EM; Romach MK; Leiderman DB
    Neuropharmacology; 2018 Nov; 142():116-134. PubMed ID: 29162429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines.
    Cameron LP; Patel SD; Vargas MV; Barragan EV; Saeger HN; Warren HT; Chow WL; Gray JA; Olson DE
    ACS Chem Neurosci; 2023 Feb; 14(3):351-358. PubMed ID: 36630260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preface to the special issue "Psychedelics and Neurochemistry".
    Nichols CD; Nichols DE
    J Neurochem; 2022 Jul; 162(1):7-8. PubMed ID: 35699130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Classic psychedelic drugs and their potential therapeutic effect].
    Bayat M
    Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in the Top-Cited Articles on Classic Psychedelics.
    Lawrence DW; Sharma B; Griffiths RR; Carhart-Harris R
    J Psychoactive Drugs; 2021; 53(4):283-298. PubMed ID: 33535907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
    De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
    Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychedelic-inspired approaches for treating neurodegenerative disorders.
    Saeger HN; Olson DE
    J Neurochem; 2022 Jul; 162(1):109-127. PubMed ID: 34816433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What can neuroscience tell us about the potential of psychedelics in healthcare? How the neurophenomenology of psychedelics research could help us to flourish throughout our lives, as well as to enhance our dying.
    Mackenzie R
    Curr Drug Abuse Rev; 2014; 7(3):136-45. PubMed ID: 25563449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.
    Sexton JD; Crawford MS; Sweat NW; Varley A; Green EE; Hendricks PS
    J Psychopharmacol; 2019 Sep; 33(9):1058-1067. PubMed ID: 30816808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine.
    Fattore L; Piva A; Zanda MT; Fumagalli G; Chiamulera C
    Psychopharmacology (Berl); 2018 Feb; 235(2):433-445. PubMed ID: 29178010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Culture, context, and ethics in the therapeutic use of hallucinogens: Psychedelics as active super-placebos?
    Dupuis D; Veissière S
    Transcult Psychiatry; 2022 Oct; 59(5):571-578. PubMed ID: 36263513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation.
    Wolf G; Singh S; Blakolmer K; Lerer L; Lifschytz T; Heresco-Levy U; Lotan A; Lerer B
    Mol Psychiatry; 2023 Jan; 28(1):44-58. PubMed ID: 36280752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Out of the box: A psychedelic model to study the creative mind.
    Kuypers KPC
    Med Hypotheses; 2018 Jun; 115():13-16. PubMed ID: 29685188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. More than meets the eye: The role of sensory dimensions in psychedelic brain dynamics, experience, and therapeutics.
    Aqil M; Roseman L
    Neuropharmacology; 2023 Feb; 223():109300. PubMed ID: 36334767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.